Thr693
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr693  -  EGFR (human)

Site Information
RELVEPLtPsGEAPN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448054

In vivo Characterization
Methods used to characterize site in vivo:
2D analysis ( 72 ) , [32P] bio-synthetic labeling ( 68 , 69 , 72 , 73 ) , immunoprecipitation ( 4 ) , mass spectrometry ( 1 , 2 , 6 , 7 , 8 , 9 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 20 , 21 , 22 , 23 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 ) , mutation of modification site ( 4 , 71 , 72 ) , peptide sequencing ( 73 ) , phospho-antibody ( 4 , 14 , 24 , 30 , 59 , 71 ) , phosphoamino acid analysis ( 68 , 69 , 72 , 73 ) , phosphopeptide mapping ( 68 , 69 , 72 , 73 ) , western blotting ( 4 , 14 , 24 , 30 )
Disease tissue studied:
bone cancer ( 33 ) , osteosarcoma ( 33 ) , breast cancer ( 4 , 11 , 12 , 18 ) , breast ductal carcinoma ( 11 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 , 11 ) , cervical cancer ( 36 ) , cervical adenocarcinoma ( 36 ) , colorectal cancer ( 58 ) , colorectal carcinoma ( 58 ) , gastric cancer ( 20 , 21 , 22 , 23 ) , gastric carcinoma ( 20 , 21 , 22 , 23 ) , leukemia ( 40 ) , acute lymphocytic leukemia ( 29 ) , acute myelogenous leukemia ( 40 ) , lung cancer ( 7 , 14 , 18 , 25 , 26 , 27 , 30 , 37 , 38 , 58 ) , non-small cell lung cancer ( 14 , 18 , 26 , 27 , 37 , 38 ) , non-small cell lung adenocarcinoma ( 7 , 14 , 26 , 27 ) , ovarian cancer ( 11 ) , pancreatic ductal adenocarcinoma ( 15 )
Relevant cell line - cell type - tissue:
'pancreatic, ductal'-pancreas ( 15 ) , 293 (epithelial) ( 4 , 9 , 42 ) , 3T3-L1 (fibroblast) ( 72 ) , 786-O (renal) ( 6 ) , 786-O (renal) [VHL (human), transfection] ( 6 ) , A431 (epithelial) ( 60 , 73 ) , A498 (renal) ( 32 ) , A549 (pulmonary) ( 14 , 16 , 25 , 58 ) , B82 (fibroblast) ( 71 ) , bone marrow ( 29 , 40 ) , breast ( 2 , 11 ) , BT-20 (breast cell) ( 18 ) , BT-474 (breast cell) ( 4 ) , BT-549 (breast cell) ( 18 ) , Chang liver (hepatic) ( 54 ) , CHO (fibroblast) [EphB1 (human), transfection] ( 72 ) , CHO-K1 (fibroblast) ( 59 ) , CL1-0 (pulmonary) ( 30 ) , CL1-1 (pulmonary) ( 30 ) , CL1-2 (pulmonary) ( 30 ) , CL1-5 (pulmonary) ( 30 ) , ECV304 (endothelial) ( 61 ) , H2009 (pulmonary) ( 18 ) , H2887 (pulmonary) ( 18 ) , H322 (pulmonary) ( 18 ) , HCC1359 (pulmonary) ( 18 ) , HCC1937 (breast cell) ( 18 ) , HCC366 (pulmonary) ( 18 ) , HCC4006 (pulmonary) ( 18 ) , HCC78 (pulmonary) ( 18 ) , HCC827 (pulmonary) ( 18 , 26 ) , HCT116 (intestinal) ( 58 ) , HeLa (cervical) ( 1 , 8 , 14 , 17 , 24 , 28 , 34 , 35 , 39 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 52 , 55 , 56 , 57 , 61 , 67 ) , HeLa S3 (cervical) ( 36 , 51 ) , HeLa_Meta (cervical) ( 31 ) , HeLa_Pro (cervical) ( 31 ) , HeLa_Telo (cervical) ( 31 ) , HMLER ('stem, breast cancer') ( 12 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 12 ) , HOP62 (pulmonary) ( 18 ) , HT-29 (intestinal) ( 62 , 63 , 64 , 65 , 66 ) , K562 (erythroid) ( 17 ) , LCLC-103H (pulmonary) ( 18 ) , liver ( 13 ) , lung ( 37 , 38 ) , MCF-7 (breast cell) ( 18 ) , MDA-MB-231 (breast cell) ( 18 ) , MDA-MB-453 (breast cell) ( 4 ) , MDA-MB-468 (breast cell) ( 18 , 59 ) , MKN-45 (gastric) ( 20 , 21 , 22 , 23 ) , MV4-11 (macrophage) ( 41 ) , NA (squamous) ( 68 , 69 ) , NCI-H1395 (pulmonary) ( 18 ) , NCI-H1568 (pulmonary) ( 18 ) , NCI-H2030 (pulmonary) ( 18 ) , NCI-H2073 (pulmonary) ( 27 ) , NCI-H647 (pulmonary) ( 18 ) , ovary ( 11 ) , PC9 (pulmonary) ( 7 ) , PC9-IR (pulmonary) ( 7 ) , TERT20 ('stem, mesenchymal') ( 53 ) , U2OS (bone cell) ( 33 ) , WI-38 (fibroblast) ( 72 )

Upstream Regulation
Kinases, in vitro:
ERK1 (human) ( 70 ) , ERK2 (human) ( 70 ) , P38A (human) ( 59 )
Treatments:
calphostin_C ( 69 ) , cell_adhesion ( 61 ) , cisplatin ( 59 ) , EGF ( 14 , 55 , 56 , 61 , 68 , 69 , 71 , 72 , 73 ) , erlotinib ( 26 ) , gomisin_A ( 24 ) , gomisin_N ( 24 ) , H2O2 ( 68 ) , IGF-1 ( 72 ) , ischemia ( 11 ) , metastatic potential ( 30 ) , nocodazole ( 36 ) , PDGF ( 72 ) , phorbol_ester ( 4 , 69 , 71 , 72 ) , SB202190 ( 59 ) , SB600125 ( 59 ) , serum ( 72 , 73 ) , staurosporine ( 69 ) , TNF ( 14 , 24 ) , U0126 ( 59 ) , vanadate ( 61 )

Downstream Regulation
Effects of modification on EGFR:
molecular association, regulation ( 72 ) , receptor internalization, altered ( 59 , 69 , 71 )
Induce interaction with:
EGF (human) ( 72 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Kawasaki Y, et al. (2016) Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain. Sci Rep 6, 31502
27531070   Curated Info

5

Jiang H, et al. (2015) Sulfiredoxin Promotes Colorectal Cancer Cell Invasion and Metastasis through a Novel Mechanism of Enhancing EGFR Signaling. Mol Cancer Res 13, 1554-66
26290602   Curated Info

6

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

7

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

8

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

9

Wang R, et al. (2014) Global discovery of high-NaCl-induced changes of protein phosphorylation. Am J Physiol Cell Physiol 307, C442-54
24965592   Curated Info

10

Tong J, Taylor P, Moran MF (2014) Proteomic analysis of the epidermal growth factor receptor (EGFR) interactome and post-translational modifications associated with receptor endocytosis in response to EGF and stress. Mol Cell Proteomics 13, 1644-58
24797263   Curated Info

11

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

12

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

13

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

14

Zhou Y, et al. (2014) p38-Mediated phosphorylation of Eps15 endocytic adaptor protein. FEBS Lett 588, 131-7
24269888   Curated Info

15

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

16

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

17

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

18

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

19

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

20

Mulhern D (2012) CST Curation Set: 13402; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

21

Mulhern D (2012) CST Curation Set: 13405; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

22

Mulhern D (2012) CST Curation Set: 13458; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

23

Mulhern D (2012) CST Curation Set: 13459; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

24

Waiwut P, et al. (2011) Gomisin N enhances TNF-α-induced apoptosis via inhibition of the NF-κB and EGFR survival pathways. Mol Cell Biochem 350, 169-75
21188622   Curated Info

25

Yu G, et al. (2011) Phosphoproteome profile of human lung cancer cell line A549. Mol Biosyst 7, 472-9
21060948   Curated Info

26

Zhang G, et al. (2011) Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity. J Proteome Res 10, 305-19
21080693   Curated Info

27

Rikova K (2011) CST Curation Set: 10908; Year: 2011; Biosample/Treatment: cell line, NCI-H2073/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

28

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

29

Gu TL, et al. (2011) Survey of activated FLT3 signaling in leukemia. PLoS One 6, e19169
21552520   Curated Info

30

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

31

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

32

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

33

Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32
20058876   Curated Info

34

Moritz A (2010) CST Curation Set: 9056; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

35

Moritz A (2010) CST Curation Set: 9057; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

36

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

37

Rikova K (2009) CST Curation Set: 8552; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391
Curated Info

38

Rikova K (2009) CST Curation Set: 8546; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391
Curated Info

39

Tong J, et al. (2009) Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041. Mol Cell Proteomics 8, 2131-44
19531499   Curated Info

40

Gu T (2009) CST Curation Set: 7661; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

41

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

42

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

43

Chen Y, et al. (2009) Combined integrin phosphoproteomic analyses and small interfering RNA--based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res 69, 3713-20
19351860   Curated Info

44

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

45

Zhou J (2009) CST Curation Set: 6253; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

46

Zhou J (2009) CST Curation Set: 6252; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

47

Moritz A (2008) CST Curation Set: 5068; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

48

Moritz A (2008) CST Curation Set: 5069; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

49

Moritz A (2008) CST Curation Set: 5078; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

50

Moritz A (2008) CST Curation Set: 5079; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

51

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

52

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

53

Thingholm TE, et al. (2008) TiO2-Based Phosphoproteomic Analysis of the Plasma Membrane and the Effects of Phosphatase Inhibitor Treatment. J Proteome Res 7, 3304-3313
18578522   Curated Info

54

Sui S, et al. (2008) Phosphoproteome analysis of the human Chang liver cells using SCX and a complementary mass spectrometric strategy. Proteomics 8, 2024-34
18491316   Curated Info

55

Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51
18220336   Curated Info

56

Liang X, et al. (2007) Quantitative Comparison of IMAC and TiO(2) Surfaces Used in the Study of Regulated, Dynamic Protein Phosphorylation. J Am Soc Mass Spectrom 18, 1932-44
17870612   Curated Info

57

Erba EB, et al. (2007) Quantitation of multisite EGF receptor phosphorylation using mass spectrometry and a novel normalization approach. J Proteome Res 6, 2768-85
17523611   Curated Info

58

Wissing J, et al. (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol Cell Proteomics 6, 537-47
17192257   Curated Info

59

Winograd-Katz SE, Levitzki A (2006) Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 25, 7381-90
16785992   Curated Info

60

Wu SL, et al. (2006) Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA). Mol Cell Proteomics 5, 1610-27
16799092   Curated Info

61

Boeri Erba E, et al. (2005) Systematic analysis of the epidermal growth factor receptor by mass spectrometry reveals stimulation-dependent multisite phosphorylation. Mol Cell Proteomics 4, 1107-21
15901825   Curated Info

62

Moritz A (2005) CST Curation Set: 658; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

63

Moritz A (2005) CST Curation Set: 659; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

64

Moritz A (2005) CST Curation Set: 800; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

65

Moritz A (2005) CST Curation Set: 660; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

66

Moritz A (2005) CST Curation Set: 661; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

67

Beausoleil SA, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A 101, 12130-5
15302935   Curated Info

68

Gamou S, Shimizu N (1995) Hydrogen peroxide preferentially enhances the tyrosine phosphorylation of epidermal growth factor receptor. FEBS Lett 357, 161-4
7805884   Curated Info

69

Gamou S, Shimizu N (1994) Calphostin-C stimulates epidermal growth factor receptor phosphorylation and internalization via light-dependent mechanism. J Cell Physiol 158, 151-9
7505275   Curated Info

70

Gonzalez FA, Raden DL, Davis RJ (1991) Identification of substrate recognition determinants for human ERK1 and ERK2 protein kinases. J Biol Chem 266, 22159-63
1939237   Curated Info

71

Heisermann GJ, et al. (1990) Mutational removal of the Thr669 and Ser671 phosphorylation sites alters substrate specificity and ligand-induced internalization of the epidermal growth factor receptor. J Biol Chem 265, 12820-7
2115882   Curated Info

72

Countaway JL, Northwood IC, Davis RJ (1989) Mechanism of phosphorylation of the epidermal growth factor receptor at threonine 669. J Biol Chem 264, 10828-35
2543683   Curated Info

73

Heisermann GJ, Gill GN (1988) Epidermal growth factor receptor threonine and serine residues phosphorylated in vivo. J Biol Chem 263, 13152-8
3138233   Curated Info